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Abstract: The vaginal ecosystem is important for women’s health and for a successful reproductive
life, and an optimal host-microbial interaction is required for the maintenance of eubiosis. The vaginal
microbiota is dominated by Lactobacillus species in the majority of women. Loss of Lactobacillus
dominance promotes the colonization by anaerobic bacterial species with an increase in microbial
diversity. Vaginal dysbiosis is a very frequent condition which affects the immune homeostasis,
inducing a rupture in the epithelial barrier and favoring infection by sexually transmitted pathogens.
In this review, we describe the known interactions among immune cells and microbial commensals
which govern health or disease status. Particular attention is given to microbiota compositions which,
through interplay with immune cells, facilitate the establishment of viral infections, such as Human
Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), Herpes Simplex Virus 2 (HSV2).
Keywords: vaginal microbiota; HIV; HPV; HSV2; cytokines; chemokines; innate immunity;
adaptive immunity
1. The Vaginal Ecosystem
The vaginal mucosal ecosystem is comprised of a stratified squamous epithelium covered by
a mucosal layer continuously lubricated by cervicovaginal fluid (CVF), which contains products
of epithelial cells, such as mucins and antimicrobial molecules B-Defensin, Lipocalin, Elafine and
secretory leukocyte protease inhibitor (SLPI) [1,2], IgA and IgG antibodies produced by mucosal
plasma cells. CVF continuously lubricates epithelium, maintains the fluidity of the ecosystem and
represents the first line of defense against exogenous pathogen colonization through the activity of
mucins which entrap microbes and facilitate their binding to antibodies [3].
Cervicovaginal fluid also helps to contain the vaginal microbiota, microbial communities which
exist in a mutualistic relationship with the host. The vaginal microbiota is unique in that, in many
women, it is most often dominated by Lactobacillus species [4,5]. The latter produce lactic acid and
bacteriocins, which contribute to prevent bacterial growth and, by maintaining a low vaginal pH
(3.0–4.5), eventually favor Lactobacillus dominance. Moreover, Lactobacillus species adhere to epithelial
surfaces, preventing the adhesion of bacteria able to infect epithelial cells, promote the autophagy
of cells infected by viruses, bacteria or protozoa, facilitating their elimination [6], and modulate any
inflammatory process that could have negative consequences, especially during pregnancy [7].
These activities are also necessary to prevent immune reactions against sperm. It is believed that
the human behavior with sexual activities at any time during the menstrual cycle, as well as during
gestation, may have contributed to select Lactobacillus species in the vaginal microbiota.
The detailed composition of vaginal microbiota and the relative abundance of the bacterial species
has recently been defined through high-throughput 16s rRNA gene sequencing. At least five microbial
communities, here referred as Community State Type (CST) were identified. Four CSTs are dominated
by Lactobacillus (L.) species highly adapted to the vaginal environment [4,5]. In particular CST-I is
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dominated by Lactobacillus crispatus; CST-II by Lactobacillus gasseri; CST-III by Lactobacillus iners; CST-V
by Lactobacillus jensenii. The CST-IV is comprised by polymicrobial communities, with prevalence
of strictly anaerobic species of the order Gardnerella, Atopobium, Mobiluncus, Megasphoera Prevotella,
Streptococcus, Mycoplasma, Ureaplasma, Dialister, Bacteroides, etc. [4,8,9]. The latter CST is very common
in black and Hispanic women, ranging from 10% in United States [4] to 60% in South Africa [10].
The factors driving racial and geographic differences in cervicovaginal communities are not known
yet, but could include changes in sexual behavior, hygienic practices, rectal colonization or even host
genetics [11].
In many cases, a low vaginal pH may be maintained by microbes of CST-IV through the production
of lactic acid [9], in this case, the presence of CST-IV is completely asymptomatic. However, loss of
Lactobacillus dominance facilitates Bacterial Vaginosis (BV), the most common vaginal infection in
reproductive-aged women [12,13], characterized by vaginal discharge, irritation, fishy odor and a
vaginal pH often >4.5. Hormonal changes strongly affect the composition of vaginal microbiota during
a woman’s life, in particular at menopausal age, when reduced estrogen levels decrease the glycogen
availability with the consequent depletion in Lactobacillus species [14].
In addition to epithelial cells and microbiota, the vaginal ecosystem comprises also cells of
innate and adaptive immunity as neutrophils, macrophages, classic dendritic cells, Langerhans cells,
NK cells, T and B lymphocytes. [15]. CD3+ T lymphocytes, predominantly CD8+ lymphocytes, are
distributed in the lamina propria of the cervix and vagina. In particular, in ectocervical mucosa
they have an effector/memory (CD27− CD45RA−) or effector phenotype (CD27−CD45RA+); B cells
are found as aggregates or follicular-like structures surrounded by T lymphocytes. Plasma cells,
as well as a small number of macrophages CD68+ and dendritic cells, are distributed throughout
the lamina propria. Dendritic cells and monocyte/macrophagic CD14+ cells represent the most
prevalent antigen-presenting cells in the vaginal ecosystem. Immune cell trafficking and activation
throughout the reproductive tract is tightly mediated by the expression of pattern recognition receptors
(PRR) [16,17] and is regulated by endocrine signaling [18].
2. Interplay between Host and Vaginal Microbiota in Health and Disease
Interplay between the cervicovaginal microbiota and the cells of immune system is determinant
to prevent infections by external pathogens and to maintain an immuno-tolerant environment,
particularly during pregnancy. Sex hormones are key regulators of this interplay: they regulate the
production of antimicrobial peptides (beta-defensin, alpha Defensin, SLPI) and of pro-inflammatory
cytokines (IL-6, IL-8) by the vaginal epithelial cells to ensure, when necessary, survival of sperm and to
prevent ascending infections [19]; estrogens in particular also contribute to select microbial populations.
At prepuberal age, vaginal microbiota is dominated by anaerobic species of the Enterobacteriacee
and/or Staphylococcacee family. At puberty, the increased concentrations of estrogens promote
the accumulation of glycogen by mature epithelial cells. Maltotriose and alpha-dextrins, derived
from alpha-amylase-mediated glycogen digestion are selective food for Lactobacillus species that use
these products for the synthesis of lactic acid. The low pH, the maintenance of mucous viscosity
and the prevention of bacterial binding on epithelial surfaces are all factors that favor Lactobacillus
dominance [20].
When Lactobacillus dominance is lost and microbial diversity increases, changes in immune
and epithelial homeostasis often appear, induced through multiple mechanisms, as: (a) production
of pro-inflammatory cytokines and chemokines, (b) recruitment of immune cells (c) reduction
in the viscosity of the CVF, due to the production of mucin-degrading enzymes (including
sialidase, α-fucosidase, α-and β-galactosidase, N-acetyl-glucosaminidase, and glycine and arginine
aminopeptidases [21,22]. Physical/chemical changes in vaginal ecosystem ultimately affect the barrier
properties of both CVF and the genital epithelium and increase the risk of infection with sexually
transmitted pathogens. In fact, vaginal dysbiosis was associated with increased risk of acquisition of
Sexual Transmitted Infections (STI) such as Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas
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vaginalis, Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV), and Human Immunodeficiency
Virus (HIV) [12,13]. Even in the absence of clinical symptomatology, women harboring CST-IV in
vaginal microbiota may be at high risk of STI or of early pregnancy loss and pre-term delivery [20].
STI impose major health and economic burdens globally, in particular in low- and middle-income
countries (LMICs) [23]. It is estimated that about 18.9 million people, of whom 48% aged 15 to 24 years,
acquired a new STI every year [24]. This is likely an underestimation of the real incidence of STI, as
they are often asymptomatic.
Sexually transmitted viral infections, the subject of this review, also represent a serious health
problem globally. A total of 34 million people were living with HIV at the end of 2011. Worldwide
prevalence of genital HPV infection is estimated at 440 million persons, causing 510,000 cases of
cervical cancer and approximately 288,000 deaths [25]. An estimated 417 million people aged 15–49
(11%) worldwide have Herpes Simplex Virus type 2 (HSV-2) infection, and HSV-2 incidence was 23.6
million new cases per year [26]. Prevalence of HSV-2 infection was estimated to be highest in Africa
(31.5%), followed by the Americas (14.4%). It increases with age, though the highest numbers of people
newly-infected were adolescents [27].
Risk factors commonly associated with acquisition of STI include biological and behavioral factors,
number of sexual partners, lack of information about transmission modalities, difficulty to access
to prevention services and, as reported above, selected compositions of the vaginal microbiota [28].
Moreover, the epidemiology of these infections is extremely complicated by the fact that each of them
increases the risk of contracting other STI.
Metagenomic studies largely contributed to define the microbial communities most frequently
associated with these infections. The assessment of the interplay among microbial communities,
immune cells reactivity and epithelial homeostasis has contributed to define the environment in which
infections are established and, in particular for HPV infection, also the one that facilitates persistence of
the pathogen. This information will be helpful for the development of new diagnostic assays as well as
new therapeutic strategies based on the replacement of harmful microbial communities. The following
sections describe in greater detail current knowledge on the interplay between vaginal microbiota,
immune system and epithelial cells in the most prevalent sexually transmitted viral infections: HIV,
HPV, HSV-2.
3. The Vaginal Microbiota and HIV Infection
The importance of understanding how bacterial communities modulate female genital health
has come strongly into focus, in particular with the evolving knowledge about the influence of
cervicovaginal microbiota on HIV acquisition. As known, the highest incidence of HIV infections, with
an extraordinarily high number of infected women in reproductive age, is in the African continent and,
particularly in the sub-Saharan regions.
Socio-economic factors largely contribute to such high incidence. The prevalence of CST-IV
in the vaginal microbiota of African women, however, also suggested that this CST may affect the
susceptibility to HIV infection. The molecular mechanisms that have been suggested are:
(A) A decrease in D-lactate concentrations and the lowering of virions trapping. In fact, D-lactate,
the main metabolic product of numerous Lactobacillus species, including L. crispatus, contributes to
trap virions by favoring hydrogen bridges between HIV surface proteins and carboxylic groups of
mucins [29].
(B) CST-IV microbes produce enzymes that degrade the mucus included sialidase, α-fucosidase,
α-and β-galactosidase, N-acetyl-glucosaminidase, and glycine and arginine aminopeptidases [21,22,30].
(C) Antigen-presenting cells activated by bacterial products, in particular LPS, produce cytokines
and chemokines which increase the recruitment of activated CD4+ lymphocytes [10].
The first observations on the associations between defined microbial communities and HIV
susceptibility were obtained in cross-sectional studies. These studies have a serious limitation since
the recruited people were at “high risk” of infection (e.g., sex workers) and left the doubt that changes
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in the microbiome may be a consequence of HIV infection rather than a contributing cause [10,31–33].
Recently, however, these doubts have been resolved: a prospective study on a cohort of healthy
HIV-uninfected black South African women who were monitored for incident HIV infection clearly
showed that none of the women who acquired HIV had a L. crispatus dominant community [34]; in
contrast, women belonging to CST-IV experienced up to four-fold greater rates of HIV acquisition
during follow-up compared to women of the CST-I, dominated by L. crispatus [34]. In particular, a
subgroup of CST-IV dominated by Prevotella bivia, Prevotella melaninogenica, Veillonella montpellierensis,
Mycoplasma species, and Sneathia sanguinegens was identified as the cervicotype with significantly
higher risk of HIV acquisition [34]. Recent observations expanded the number of bacterial taxa
associated with increased risk of HIV acquisition: in addition to Prevotella species, Parvimonas species
type 1 and type 2, Gemella asaccharolytica, Eggerthella species type 1 and vaginal Megasphaera species
were significantly associated with HIV acquisition [35].
The mechanisms underlying the increased HIV susceptibility likely reside in the ability of the
bacterial taxa to induce a strong inflammation in the cervicovaginal environment with elevated
concentrations of IL-17, IL-23 and IL-1β and high recruitment of CCR5+ CD4 T cells, the primary
target of HIV infection. These cells also show an activated phenotype (HLA-DR+CD38+) and thus they
are highly permissive for viral replication [34]. High numbers of activated γδ CD4 T lymphocytes
expressing the Vδ2 chain, which potentially are targets of HIV and permissive for its replication, were
also found increased in women with vaginal microbiota not dominated by Lactobacillus species [36],
thus defining a framework where selected microbial communities are closely linked with immune
activation and HIV infection.
Such knowledge also suggests that, in addition to vaccines, strategies to prevent HIV infection
may include the stable colonization of vaginal microbiota with non-dangerous bacterial taxa to limit
inflammation and T-cell recruitment. Since vaginal dysbiosis may undermine the efficacy of locally
administered antiviral drugs [37], changes in vaginal microbiota will also improve the efficacy of
these drugs.
4. The Vaginal Microbiota and HPV Infection
Infection with HPV is the most common viral infection of the reproductive tract and high-risk
(HR) genital HPVs are central etiological agents in the development of cervical cancer and of its
premalignant precursor, cervical intraepithelial neoplasia (CIN) [38]. HR-HPV genotypes 16, 18, 31,
33, and 35 are the most diffuse worldwide. Other HR genotypes are HPV 39, 45, 51, 52, 56, 58, 66
and 69 [39]. Generally, HPV infects the basal layer of the cervical squamous epithelium, where viral
genomes persist as episomes at low-copy numbers [40]. High copies of virions are produced upon
differentiation of epithelial cells and the new progeny of virions may be released from the epithelial
surface. Infection of stem cell-like cells of the basal layer ensures persistence of infection [41].
The oncogenic activity of HR-HPVs is based on the functional properties of their E6 and E7
proteins [42]. These proteins inactivate p53 and retinoblastoma protein, respectively, and lead to the
inhibition of apoptosis and to cell cycle progression of cells at the basal and differentiated layers of
cervical epithelium. Viral integration with genetic alterations ultimately may induce uncontrolled
cell proliferation [43,44]. At the histological level, different grades of squamous intraepithelial lesions
are the result of persistent HR-HPV infection and, if undetected and untreated, they may lead to
high-grade lesions and cancer in an average of 5 to 15 years [45].
The immune response to acute HPV infections is initially mediated by mucosal NK cells [46,47]
and by epithelial cells which produce antimicrobial peptides with reported anti-viral effects [48].
However, HR-HPVs have evolved molecular strategies to escape innate and adaptive immunity [49–52].
HR-HPV infection never associates with a marked pro-inflammatory environment [53–55]. A rather
high number of CD4+ CD25+ regulatory T cells and the presence of activated TH2 cells were reported in
HR-HPV persistent infections and associated with the suppression of cytotoxic functions, induction of T
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cell anergy [56,57]. Consequently, virus-induced immune suppression may be responsible for increased
infection with other sexually transmitted diseases such as Chlamydia trachomatis infection [58,59].
Emerging data support the notion that the vaginal microbiome is involved in the natural history
of the disease [46].
Since HPV infections, even with HR genotypes, may be transient and more than 50% of them are
cleared within six months while almost 90% are cleared within two years, we believe it is critical to
consider data obtained in longitudinal studies and to devote special attention to the context in which
they were obtained [4,46]. The first longitudinal study observed a cohort of 32 North American sexually
active and premenopausal women over the course of 16 weeks using self-sampling at twice-weekly
intervals [14]. A total of 930 samples of cervicovaginal mucous were obtained and microbiota studies
revealed that women with CSTs III (dominance of L. iners) or with a subtype of CST-IV with a high
proportion of Atopobium, Prevotella, Gardnerella species were most likely to be HPV positive and had
the slowest rate of infection clearance.
In a subsequent survey, Di Paola et al. [30] used cervicovaginal samples collected in a study for
HR-HPV screening program in Italy. A total of 55/1029 samples were positive for HR-HPV at the
baseline screening. The authors used the results of the second HR-HPV screening performed after one
year to stratify the baseline sampling in Clearance group, with no evidence of HR-HPV DNA after one
year; the Persistence group, HR-HPV+ with at least one of the HPV-DNA genotypes of the baseline
sampling after one year. A group of cervicovaginal samples from women negative for HR-HPV
(HR-HPV−) infections was included as a control. The results of this study showed that a subgroup of
CST-IV dominated by strictly anaerobic species (Gardnerella, Prevotella, Atopobium, Megasphoera) was
prevalent in the Persistence group, compared with either the Clearance or Control group. Odds ratio
analysis confirmed that this CST may be a risk factor for the persistence of HR-HPV infection.
In agreement with previous reports [60,61], a significant enrichment in Sneathia and Megasphaera
was found in the group of HR-HPV+ women, compared to HR-HPV− controls, while the Atopobium
genus was significantly enriched in Persistence group, compared to the other groups.
Although the association of bacterial vaginosis with higher rates of HPV infection and persistence
has been known from a long time [62], metagenomic data revealed that selected microbiota
compositions increase the risk of infection, even in the total absence of clinical symptomatology.
While it is quite clear that some microbial communities favor HPV infection by modifying the barrier
effect of cervical mucus and of stratified epithelium, the effects of microbiota-related immunological
changes on the outcomes of HPV infection are not elucidated yet. This may depend on the impact
of HPV infection on the host’s immune defenses [53,54], and on the mucosal metabolism which can
also affect the composition of the vaginal microbiota. Therefore, the immunological signature of HPV
infection on vaginal microbiota has to be further elucidated and more data are needed to have a full
understanding of how HPV infections are modulated by the vaginal environment.
Persistent infection with HR-HPV is a necessary, but not sufficient, condition for the development
of cervical cancer. As soon as the establishment of HR-HPV infection occurs, cellular changes can be
observed in the cervical exfoliated cells. Persistent infections can result in different grades of squamous
intraepithelial lesions that ultimately lead to high-grade lesions and cancer in an average of 5 to 14
years if undetected and untreated [45].
Recently, much attention has been given to the role of vaginal microbiota in the progression
of epithelial lesions up to carcinogenesis. Drago et al. [63] found a strong correlation between
Ureaplasma parvum-HPV co-infection and CIN1. Mitra et al. [64] have studied a cohort of 169
women with different degrees of cervical lesions and showed that increasing severity of cervical
lesions was associated with higher vaginal microbiome diversity and decreased relative abundance
of Lactobacillus species. CST-IV was associated with increasing disease severity, irrespective of HPV
status. [61,65]. In particular, Atopobium vaginae and Lactobacillus iners were associated with an increased
risk of neoplastic progression in HPV+ women [61], while Sneathia sanguinegens [54,61,64] and other
Fusobacterial species [61], Anaerococcus tetradius and Peptostreptococcus anaerobius [64], were shown to
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be associated with an increase in disease severity. Novel bacterial taxa (Shuttleworthia, Gemella and
Olsenella) and Streptococcus agalactiae were found enriched in HPV+ women with low- and high-grade
cervical dysplasia (LGD, HGD), invasive cervical carcinoma (ICC) [54]. Sneathia spp. was the only
taxon significantly enriched both in HPV+ women without lesions of any grade and in women with
precancerous lesions and cervical cancer, suggesting that this taxon may represent a metagenomic
marker for CIN progression. In particular, Sneathia spp. were found enriched in precancerous groups,
and invasive cervical cancer, particularly in subjects of Hispanic ethnicity [54].
The molecular mechanisms through which bacteria of CST-IV may favor neoplastic progression
are: (a) they produce high levels of nitrosamines which are known carcinogens; (b) they induce DNA
oxidative damage [66].
While HPV infection or clearance is not marked by a pro-inflammatory environment, patients
with cervical dysplasia and ICC were shown to have an increase in pro-inflammatory cytokines and
chemokines (TNF-α, TNF-β, MIP-1α, GM-CSF), as well as an increase in cytokines related to adaptive
immune responses (IL-2, IL-4, SCD40L). [67]. Moreover, the concentrations of the immunomodulating
cytokine IL-10 were found to be increased in the ICC group. However, no direct association between the
increased concentrations of cytokines and chemokines and the microbiota composition was revealed.
Only the concentration of IL36γ was always elevated in patients with carcinoma, suggesting a direct
or indirect role of this cytokine in the carcinogenetic process [54]. These data strongly suggest that,
similar to other mucosal sites, chronic genital inflammation may promote carcinogenesis.
In the future it is highly likely that metabolomic studies, using nuclear magnetic resonance and
mass spectroscopy, may better define the association of vaginal microbiota composition in health
and disease states. A better definition of the effects of individual bacterial species, such as L. iners,
A. vaginae, and Sneathia species, on epithelial and immune cell functions is desirable. In fact, if the
responsibility of a single bacterial species in HPV disease is defined, it will be possible to identify
patients at higher risk using microchip array or metabolomic technologies. Moreover, it will be possible
to develop new therapeutic strategies based on pre/probiotics, in order to manipulate the vaginal
microbiota composition.
5. Herpes Simplex Virus Type-2 (HSV-2)
Herpes simplex virus type-2 (HSV-2) is a common STI worldwide and the leading cause of
genital ulcer disease [27]. Most HSV-2 infections are asymptomatic, with >80% of HSV-2 seropositive
individuals asymptomatically shedding virus. More women are infected with HSV-2 than men; in
2012 it was estimated that 267 million women and 150 million men were living with the infection.
This is because sexual transmission of HSV is more efficient from men to women than from women to
men [26].
After infection by sexual transmission, virus replication initiates in genital keratinocytes and may
spread to thousands of cells. Then, the virus invariably enters the neuron to reach the dorsal root
ganglia where lifelong latency is established [68]. Virus periodically reactivates within the ganglia and
travels back down the neuron leading to either asymptomatic, low titer shedding, or less commonly
recurrent ulcers which are typically associated with prolonged high titer shedding [69–71].
The first two studies examining the associations between HSV-2 and vaginal microbiota were
published in 2003 [72,73]. The main data emerging from these studies was that lack of Lactobacillus
protective species and a history of BV was significantly associated with HSV-2 seropositivity [72].
Additionally, prospective studies confirmed the association between prevalent HSV-2 infection and
BV [74,75]. In the case of HSV-2 infection, the association with vaginal dysbiosis is bi-directional.
HSV-2 infection indeed seems to increase the occurrence of dysbiosis by multiple mechanisms: (a) the
intermittent HSV-2 reactivation also leads to immune activation in the genital environment favouring
changes in microbiota composition [76]; (b) increased iron availability which facilitates the growth of
Gardnerella vaginalis [77]. In the same way, BV increases genital shedding of HSV-2 [73,78,79].
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HSV2 infection was extensively studied because it represents a high risk factor for HIV
acquisition [80]. This increased risk may occur because HSV-2 reactivation disrupts the epithelial
barrier and recruits activated CD4 cells, which are target cells for HIV infection, into the lesion.
Moreover, it has been shown that the HSV regulatory proteins ICP0, ICP4, VP16 upregulate HIV
replication and increase the frequency and the titer of mucosal HIV shedding. This may occur during
both clinical and asymptomatic HSV reactivation. [81,82].
Microbiota-HSV2 interactions and the corresponding changes in vaginal immunity were recently
studied through NGS technologies in a group of 51 African Caribbean and other black (ACB) HIV−
women [83]. The authors found that HSV-2 infection was associated with an increased number
of mucosal CD4+ T-cell subsets without significant alterations in local proinflammatory cytokines;
selected cytokines or antimicrobial peptides (MIP-3α, IL-6, IL-8, LL-37, and HNP1-3), associated with
the number of CD4+ T cells and these were distinct from cytokines usually associated with CST-IV,
suggesting that HSV-2 and vaginal CST-IV enhance HIV susceptibility through independent mucosal
immune mechanisms.
In murine experimental models of HSV-2 infection, Oh et al. investigated the mechanisms by
which commensal bacteria elicit immune protection against HSV-2 infection of the vaginal mucosa [84].
The authors demonstrated that vaginal dysbiosis, like that induced by antibiotic therapy, affects
the T-cell mediated adaptive immune response inducing a marked suppression. The molecular
mechanisms at the basis of immune-suppression relied on high concentrations of IL-33, an alarmin
secreted by damaged epithelial cells in the vaginal environment [85] after antibiotic treatment.
IL33 strongly inhibits the IFN-γ secretion by activated mucosal T cells, limiting the recruitment of
T cells which is required to clear viral infection. The suppressive effects of IL33 are also mediated by a
recruitment of innate lymphocytes type 2 and eosinophils into vaginal tissue, which contributes
to suppression of antiviral immunity against mucosal HSV-2 infection by producing cytokines
interfering with a TH-1 response [86]. Interestingly, protease activity by commensal bacteria resistant
to antibiotic-treatment is likely responsible for epithelial damage and IL-33 secretion. Thus, in the case
of HSV-2 infection a complex interplay among the virus, immune cells, and microbiota occurs, and it
likely increases the susceptibility to other sexually transmitted diseases, including HIV.
6. Gaps and Challenges
Despite recent advances, significant gaps in knowledge concerning the vaginal microbiota
have yet to be solved. Prevention strategies of sexually transmitted viral infection should be
mainly based on the prevention and or treatment of recurrent BV. Treatment with oral or vaginal
metronidazole or clindamycin is typically efficacious in the short term (as defined by Nugent or
Amsel criteria) but recurrence rates are high [87]. An efficient strategy in the longer term may
specifically target pathobionts or BV-associated anaerobs, while sparing Lactobacillus species or
colonizing vaginal microbiota with appropriate probiotics. Common vaginal strains as L. gasseri
and L. crispatus have been used in recurrent BV with moderate results; indeed, few randomized
trials only (all including Lactobacillus rhamnosus) showed lower rates of recurrent BV in the probiotic
group [88]. Hormonal therapy offers a potential approach to promote Lactobacillus dominant
communities [89] while treatments to maintain vaginal acidity were not able to promote a healthy
vaginal microbiota [90]. Treatments specifically targeting dysbiosis-associated anaerobes or pathobionts
while sparing Lactobacillus species combined with biofilm disrupting agents, systemic or topical
estrogen, and/or Lactobacillus-containing vaginal pro- or synbiotics might be more efficacious in the
longer term.
The definition of cervicovaginal bacteria which mediate immunomodulatory mechanisms will
help to identify molecules and to set up therapeutic strategies for infections that take advantage from a
vaginal inflammatory environment. Finally, even when effective diagnostic tools are developed, it will
be necessary to define the “harmful” levels of cervicovaginal inflammation, the appropriate "timing" of
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the therapeutic intervention and which women to target. We are confident that the progress achieved
in recent years will make it possible to find the optimum solutions for these issues.
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CVF Cervicovaginal fluid
CST Community State Type
STI Sexually transmitted infections
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